Harnessing the U.S. Taxpayer to Fight Cancer and Make Profits by MATT RICHTEL and ANDREW POLLACK

By MATT RICHTEL and ANDREW POLLACK

Public funding is backing a new immunotherapy treatment, but the bulk of any profits will go to a private company. So are taxpayers getting a good deal?

Published: December 18, 2016 at 07:00PM

from NYT Health http://ift.tt/2hjPPDW
via IFTTT

from WordPress http://ift.tt/2i3fDbz
via IFTTT